Characterisation of a lipid and lipid profile of atherogenic risk and cardiovascular morbidity and mortality in Chronic Renal Disease (stages 3 to 5) (prospective study NEFRONA) (Q3141792): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Chronic renal patients have a higher prevalence and severity of atheromatosis, but a low-risk LDL and HDL cholesterol profile according to the criteria applied to the general population. The present study will attempt to determine whether the lipid profile of these patients has differential characteristics, and whether there are nine lipid species that have a specific weight in the atheromatosis of renal patients. To do this, we will analyse lip...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Characterisation of a lipid and lipid profile of atherogenic risk and cardiovascular morbidity and mortality in Chronic Renal Disease (stages 3 to 5) (prospective study NEFRONA) | |||
Revision as of 13:24, 12 October 2021
Project Q3141792 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Characterisation of a lipid and lipid profile of atherogenic risk and cardiovascular morbidity and mortality in Chronic Renal Disease (stages 3 to 5) (prospective study NEFRONA) |
Project Q3141792 in Spain |
Statements
40,750.0 Euro
0 references
81,500.0 Euro
0 references
50.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)
0 references
41°36'53.14"N, 0°37'36.41"E
0 references
25120
0 references
Los enfermos renales crónicos presentan una mayor prevalencia y severidad de ateromatosis, pero un perfil de colesterol LDL y HDL de bajo riesgo segun los criterios aplicados a la población general. El presente estudio intentará determinar si el perfil lipídico de estos enfermos presenta características diferenciales, y si existen nueves especies lipídicas que tengan un peso específico en la ateromatosis de los enfermos renales. Para ello analizaremos las subfracciones lipídicas en los enfermos renales del estudio NEFRONA por medio de resonancia magnética nuclear. Además, realizaremos un estudio lipidómico no dirigido, por medio de cromatografía acoplada a espectrometría de masas, para determinar si existe alguna especie lipídica que se relacione con una mayor prevalencia de placa de ateroma en los enfermos renales. Por último estudiaremos la capacidad aceptora de colesterol de las HDL del plasma de los enfermos renales para determinar su funcionalidad por medio de la técnica de eflujo de colesterol desde macrófagos. Todo ello lo relacionaremos con la presencia de placa de ateroma, la severidad de la enfermedad ateromatosa (determinada por el número de placas y el área total de las mismas) y la composición de la placa (porcentaje de lípidos, fibrosis y calcificación) en un corte transversal de los pacientes del NEFRONA. Además, en una subpoblación en la que se realizó un segundo estudio vascular a los dos años, se determinará la posible relación del perfil lipídico con la progresión de la enfermedad ateromatosa. Por último, se analizará la posible relación del perfil lipídico con la aparición de eventos cardiovasculares fatales o no fatales tras seis años de seguimiento de la cohorte. (Spanish)
0 references
Chronic renal patients have a higher prevalence and severity of atheromatosis, but a low-risk LDL and HDL cholesterol profile according to the criteria applied to the general population. The present study will attempt to determine whether the lipid profile of these patients has differential characteristics, and whether there are nine lipid species that have a specific weight in the atheromatosis of renal patients. To do this, we will analyse lipid subfractions in renal patients in the NEFRONA study by means of nuclear magnetic resonance imaging. In addition, we will conduct a non-directed lypidomic study, by means of chromatography coupled to mass spectrometry, to determine if there is any lipid species that is associated with a higher prevalence of atheroma plaque in renal patients. Finally, we will study the cholesterol-acceptor capacity of HDL plasma of renal patients to determine their functionality by means of the cholesterol efflux technique from macrophages. All of this is related to the presence of atheroma plaque, the severity of the atheromatous disease (determined by the number of plates and the total area of the plaques) and the composition of the plaque (percentage of lipids, fibrosis and calcification) in a cross-section of NEFRONA patients. In addition, in a subpopulation in which a second vascular study was conducted at two years, the possible relationship of the lipid profile with the progression of the atheromatous disease will be determined. Finally, the possible relationship of the lipid profile with the occurrence of fatal or non-fatal cardiovascular events after six years of cohort follow-up will be analysed. (English)
12 October 2021
0 references
Lleida
0 references
Identifiers
PI16_01354
0 references